The value of blood interferon-gamma-inducible protein 10 level in assessing the treatment efficacy of pulmonary tuberculosis patients

doi:10.3969/j.issn.1000-6621.2019.02.011

Abstract

Abstract:

Objective To investigate the changes of serum interferon-gamma-inducible protein 10 (IP-10) and IP-10 response against tuberculosis specific antigens in QuantiFERON Gold In-Tube (QFT-GIT) assay in patients with active pulmonary tuberculosis before and after treatment. Methods A total of 161 cases of active pulmonary tuberculosis who were improved after 6-9 months of regular antituberculosis treatment in Hebei Provincial Chest Hospital during January 2017 to March 2017 were enrolled in this study. Patients were divided into anti-acid staining (+) group (82 cases) and anti-acid staining (-) group (79 cases) according to the results of sputum smear anti-acid staining before treatment. Anti-acid staining (+) group was further divided into group A (anti-acid staining change (-) after 2 months of treatment, 31 cases) and group B (anti-acid staining still (+) after 2 months of treatment, 51 cases). Anti-acid staining (-) group was defined as the group C (79 cases). The levels of serum IP-10 and IP-10 response to antigen in QFT-GIT assay were measured and compared in all groups within 2 weeks, at the end of 2 months and after 6-9 months of treatment. Results The levels of serum IP-10 within 2 weeks, at the end of 2 months and after 6-9 months of treatment were (0.16±0.03)μg/L, (0.13±0.03)μg/L and (0.09±0.02)μg/L in group A, (0.16±0.03)μg/L, (0.15±0.03)μg/L and (0.09±0.02)μg/L in group B, and (0.16±0.03)μg/L, (0.13±0.03)μg/L and (0.09±0.02)μg/L in group C, respectively. The levels of IP-10 response to antigen in QFT-GIT assay within 2 weeks, at the end of 2 months and after 6-9 months of treatment were (21.60±3.07)μg/L, (19.94±3.05)μg/L and (11.01±2.16)μg/L in group A, (23.52±3.10)μg/L, (20.50±4.60)μg/L and (12.08±3.57)μg/L in group B, and (19.67±3.32)μg/L, (13.43±3.16)μg/L and (8.72±1.08)μg/L in group C, respectively. The differences in the levels of serum IP-10 and IP-10 response to antigen in QFT-GIT assay among the three treatment time points in group A, B and C were all statistically significant (F values were 72.84, 111.92, 107.52 and 75.01, 118.09, 138.98, respectively; Ps=0.000). The levels of serum IP-10 and IP-10 response to antigen in QFT-GIT assay after the course of treatment were lower than those within 2 weeks of treatment, and the differences were statistically significant (group A: q values were 71.42 and 138.42; group B: q values were 74.68 and 150.29; group C: q values were 68.76 and 129.83; Ps=0.000). Conclusion Serum IP-10 and IP-10 response to antigen in QFT-GIT assay can be used as potential biomarkers for monitoring the treatment effect of patients with active pulmonary tuberculosis.

Key words: Tuberculosis,pulmonary, Chemokines,CXC, Treatment outcome, Discriminant analysis

Lan WEI,Xue-bo QIN,Xiao-liang DUAN,Hui LI,Yu-zhuo LI,Xin-zhuan JIA,Lei ZHANG. The value of blood interferon-gamma-inducible protein 10 level in assessing the treatment efficacy of pulmonary tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2019, 41(2): 181-185. doi: 10.3969/j.issn.1000-6621.2019.02.011

Figures/Tables 2

组别	例数	年龄 (岁, $x ˉ$ ±s)	性别 [例(构成比,%)]		BMI (kg/m²)
组别	例数	年龄 (岁, $x ˉ$ ±s)	男	女	BMI (kg/m²)
A组	31	41.98±10.23	17(54.84)	14(45.16)	20.49±1.53
B组	51	41.98±7.13	25(49.02)	26(50.98)	20.58±1.55
C组	79	42.06±9.93	37(46.84)	42(53.16)	20.58±1.77
统计检验值		F=0.06	χ²=0.57		F=0.08
P值		0.941	0.752		0.913

References 13

[1]	Phillips PP, Davies GR, Mitchison DA . Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis, 2010,10(2):69-70. doi: 10.1016/S1473-3099(09)70256-7 URL
[2]	Siddiqi K, Lambert ML, Walley J . Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis, 2003,3(5):288-296. doi: 10.1016/S1473-3099(03)00609-1 URL
[3]	Goletti D, Raja A , Syed Ahamed Kabeer B, et al. Is IP-10 an accurate marker for detecting M.tuberculosis-specific response in HIV-infected persons? PLoS One, 2010,5(9):e12577. doi: 10.1371/journal.pone.0012577 URL
[4]	中华医学会结核病学分会. 肺结核诊断和治疗指南. 中华结核和呼吸杂志, 2001,24(2):70-74.
[5]	Walrath J, Zukowski L, Krywiak A , et al. Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am J Respir Cell Mol Biol, 2005,33(1):48-55. doi: 10.1165/rcmb.2005-0060OC URL
[6]	Ruhwald M, Bjerregaard-Andersen M, Rabna P , et al. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M.tuberculosis in a whole blood based T-cell assay. BMC Res Notes, 2009,2:19. doi: 10.1186/1756-0500-2-19 URL
[7]	Chen YC, Chin CH, Liu SF , et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Dis Markers, 2011,31(2):101-110. doi: 10.1155/2011/938794 URL
[8]	Azzurri A, Sow OY, Amedei A , et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect, 2005,7(1):1-8. doi: 10.1016/j.micinf.2004.09.004 URL
[9]	Chen DY, Shen GH, Chen YM , et al. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis. Int J Tuberc Lung Dis, 2011,15(2):192-200.
[10]	Cannas A, Calvo L, Chiacchio T , et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis, 2010,10:333. doi: 10.1186/1471-2334-10-333 URL
[11]	Riou C, Perez Peixoto B, Roberts L , et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One, 2012,7(5):e36886. doi: 10.1371/journal.pone.0036886 URL
[12]	Su WL, Perng WC, Huang CH , et al. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin Vaccine Immunol, 2010,17(2):223-231. doi: 10.1128/CVI.00381-09 URL
[13]	Kabeer BS, Raja A, Raman B , et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis, 2011,11:135. doi: 10.1186/1471-2334-11-135 URL

[1]	DUAN Li-ming, DING Chao, LIU Yu-gang, WEI Lin, GU Zhen-ning. Application value of video-assisted thoracoscopic surgery in the treatment of chronic tuberculous empyema [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 850-853.
[2]	LIU Lin. Clinical analysis of 35 pregnant tuberculous pleurisy patients [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 731-736.
[3]	BAO Rui, LIU Xiao-yang, REN Peng, ZHANG Feng, LIANG Hai-yan, WANG Ru, FU Ling, GAN Di-shou. Analysis of surgical treatment characteristics in patients with spinal tuberculosis and HIV co-infection [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 645-648.
[4]	HE Min, PU Yu, CAI Yu-guo, LI Bang-yin, HE Lei, HUAN Ming-cang. Observation on the clinical effect of surgical treatment for 23 patients with spinal tuberculosis complicated with AIDS [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 454-458.
[5]	BIN Song-tao, WANG Ji, TAN Li, WU Cheng-qing, WANG Yan-chun, LI Ming. Observation on the effects of bronchoscopy diagnosis and interventional treatment in 11 children with tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 523-526.
[6]	KANG Yi,FU Man-jiao. Clinical analysis of 11 patients with severe tuberculosis in pregnancy or puerperium [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 385-390.
[7]	JIAN Yi-luan,WU Long-zhang,GU Zhuo-yun. Clinical characteristics and treatment outcomes of 18 patients with non-tuberculosis mycobacteria concerning eyes, ears, nose and throat [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 255-258.
[8]	LI Zhi-ming,YU Shan,WANG Tao.. Clinical effect analysis of Chaizhushigao Decoction in 29 recurrent fever tuberculosis patients complicated with other infections [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 121-125.
[9]	CHEN Pin-ru,TAN Shou-yong. The role of surgery in the treatment of non-tuberculous mycobacterium pulmonary disease [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 159-163.
[10]	TANG Yu-ting, SANG Ying-ying, XIA Chao. Research progress on clinical application of traditional Chinese medicine appropriate technology in the treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1339-1342.
[11]	WANG Zhen-long, WU Xiao-ying, XU Hong-mei. Clinical characteristics and therapeutic effect analysis of 23 cases of disseminated BCG disease after BCG vaccination caused by primary immunodeficiency disease [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1042-1047.
[12]	BAI Yun-song, ZHANG Xue-jun, CAO Jun, FENG Lei, QI Xin-yu, GUO Dong, YAO Zi-ming, LI Cheng-xin. Analysis of clinical efficacy of stageⅠanterior-posterior approach surgery for lumbar tuberculosis in children [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1048-1052.
[13]	ZHANG Feng, WANG Man-zhi, WEI Song-qing, ZHANG Xiao-fo, ZHOU Hai-yi. Analysis of clinical characteristics and curative effect in 17 urinary tuberculosis children [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1061-1067.
[14]	Yong-jie ZHAO,Nan-ping QIAN. Analysis of surgical treatment of 16 patients with spinal tuberculosis combined with AIDS [J]. Chinese Journal of Antituberculosis, 2019, 41(8): 838-842.
[15]	Hang-kong REN,Li-ming DUAN,Yi ZHANG,Ming-jun HU. Efficiency analysis of surgical treatment in patients suffering tuberculous empyema complicated with static cirrhosis [J]. Chinese Journal of Antituberculosis, 2019, 41(8): 843-847.